Searchable abstracts of presentations at key conferences in endocrinology

ea0019p269 | Pituitary | SFEBES2009

The management of microprolactinoma: are we following the guidelines for dopamine agonist withdrawal?

Huda M , Wee J , Kwok H , Lawrence U , Moore R , Scally L , Gibbs C , Tremble J

Background: Dopamine agonist (DA) withdrawal is common in the management of microprolactinoma. Guidelines in 19971 and 20062 suggest that DA should be withdrawn after normoprolactinaemia for 3 years.Aims: To assess DA withdrawal and adherence to guidelines.Methods: We retrospectively examined casenotes from 1997 to 2008. Patients were included with clinical and biochemical evidence of hyperprolactinaemia, and ...